Alzheimer’s Drug Leqembi Gets Standard FDA Approval

Published on July 6, 2023

The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai and Biogen’s Leqembi for patients with Alzheimer’s disease, clearing the way for wider insurance coverage of the drug. The FDA included its strongest safety warning for an approved drug, a…

Read Full Article (External Site)